Slide 1: MaxCyte Corporate Presentation
® ® ® ® TM is a trademark of MaxCyte, Inc. are registered trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT March 2025
Slide 2: Disclaimer
2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”), as amended. Reliance on this document for the purpose of engaging in any investment activity may expose an individu
Slide 3: MaxCyte at a Glance
© 2024 MaxCyte, Inc. All Rights Reserved MaxCyte at a Glance Our Mission We power the future of cell and gene therapy with innovative, scalable cell engineering solutions that enable our customers to deliver advanced therapies to patients Base-editing (CRISPR), CRISPR, ARCUS, RNA-Based Engineering,
Slide 4: Cell and Gene Therapy Development
Cell and Gene Therapy Development Cell Engineering (Electroporation) Cell Proliferation In-Vivo Ex-Vivo Viral/Non-Viral Vector for delivery to Specific Organ Tissue The engineering of cells to develop therapies addressing a host of human diseases with unmet medical needs Cells Collected from Univers
Slide 5: Addressing the Challenges of Cell & Gene Therapy Development
Addressing the Challenges of Cell & Gene Therapy Development Next-generation cell therapy programs have become increasingly complex requiring multiple edits Regulatory risk increases with new unknowns (donor cells, next-gen approaches, new indications) Vein-to-vein manufacturing times are high; opti
Slide 6: Large Opportunity in Ex-Vivo Cell and Gene Therapy
Large Opportunity in Ex-Vivo Cell and Gene Therapy MaxCyte # of Potential SPLs Research & Discovery Pre-Clinical Clinical Commercial 124 Programs 82 Non-Viral Programs (66%) 383 Programs 193 Non-Viral Programs (50%) 249 Programs 84 Non-Viral Programs (37%) 10 Programs 1 Non-Viral Program (10%) Ex-Vi
Slide 7: The ExPERT Platform Enabling Non-Viral Cell Engineering
The ExPERT PlatformTM Enabling Non-Viral Cell Engineering Full scale RUO Small/mid-scale RUO Large Scale RUO/cGMP Full scale RUO/cGMP 75 thousand to 700 million cells 75 thousand to 20 billion cells 5 billion to 200 billion cells 75 thousand to 20 billion cells High Performance: • >90% transfection
Slide 8: MaxCyte's Solutions Span Cell & Gene Engineering
MaxCyte’s Solutions Span Cell & Gene Engineering Industry-leading, scalable ExPERT Electroporation Platform and best-in-class customer support Commercial Strategic platform license for clinical & commercial manufacturing IND-enabling lease Discovery Process Development IND-enabling activities IND-en
Slide 9: Flow Electroporation technology integrates within a closed cGMP workflow
MaxCyte’s Flow Electroporation® technology integrates efficiently within a closed cGMP cell therapy workflow Cell Isolation & Expansion CCBE Electroporation Cell Expansion Cryopreservation Add loading agent (mRNA, pDNA, RNP…) and Electroporate Process cells on different platforms Wash media and exch
Slide 10: Development of Ex Vivo Cell Therapies Requires Highly Specialized Engineering Tools and Assays
Development of Ex Vivo Cell Therapies Requires Highly Specialized Engineering Tools and Assays 10 Lentivirus Adeno-associated virus Lipid nanoparticles Electroporation Engineering Tools Delivery Technologies CRISPR/Cas gene editing Transposase integration mRNA transient expression Stable DNA transdu
Slide 11: MaxCyte's Solutions are Uniquely Positioned to Support Cell Therapy Development
MaxCyte’s Solutions are Uniquely Positioned to Support Cell Therapy Development Flow Electroporation® technology facilitates multiplex and sequential engineering without the payload and capacity limitations of viral approaches 33+ Field Application Scientists support our customers in their developme
Slide 12: Platform Generates Recurring Revenue in Pre-Clinical, Clinical, and Commercial
MaxCyte’s Platform Generates Recurring Revenue in Pre-Clinical, Clinical, and Commercial 12 © 2024 MaxCyte, Inc. All Rights Reserved Razor/Razor Blade Economics Full scale RUO Preclinical and Academic Revenue Model Instrument Sale Clinical and Commercial Revenue Model Annual License Fee Razor/Razor
Slide 13: MaxCyte's Strategic Platform Licenses (SPLs)
MaxCyte’s Strategic Platform Licenses (SPLs) 1 Commercial Program* 29 SPL Customers 18 Programs are currently in clinical development* Cleared INDs or Equivalent *Updated as of December 31, 2024 Strategic relationships with leading cell therapy developers in clinical development and with commercial
Slide 14: Typical MaxCyte SPL Economics
Typical MaxCyte SPL Economics Early Clinical: (Phase 1/2) Years 1-3 • Mid 6-figure up to low 7-figure milestones • 1-3+ instruments + disposables Mid-late Clinical: (Phase 2/3) Years 3-5+ • 7-figure milestone • Increasing instrument and disposables usage Approval: Year 5+ • Multiple 7-figure milesto
Slide 15: Highly Technical Employees: Field Application Scientists and Commercial Team
Highly Technical Employees Field Application Scientists (FAS) and Commercial Team Unparalleled scientific support to customers Customer relationships at early stages of cell & gene therapy development Signed SPL *Updated as of December 31, 2024 MaxCyte has a team of 33+ highly trained FAS* Global te
Slide 16: Indications in Active MaxCyte-Enabled Clinical Trials
16 © 2025 MaxCyte, Inc. All Rights Reserved As of March 2025 / Includes SPL Clinical Trials Allogeneic Autologous Cell Approach Phase 1 Phase 1/2 Pivotal Commercial Clinical Phase HSCs Other cell types HSCs T-cells T-cells Trem-cel (Vor Biopharma) Nula-Cel (Kamau Therapeutics) CB010 (NHL) (Caribou B
Slide 17: SPL Case Study: CASGEVY
SPL Case Study: CASGEVY® CASGEVY® for Sickle Cell Disease (SCD) and for Transfusion-Dependent Beta-Thalassemia (TDT) (2023 and 2024) 2013 – MaxCyte supports Inception Genomics (Changed name to CRISPR Therapeutics AG in 2014) ▪ Support for programs in research 2018 – Vertex/CRISPR achieves IND Milest
Slide 18: MaxCyte Supports the Future of Cell & Gene Therapies
1 Approved Partner Program Launched: 2023 SPL Program: Vertex’s Exa-Cel Indications: Sickle Cell Disease Beta-Thalassemia 8 Potential Approved Partner Programs Launch Potential: 2027-2028 Indications: Lymphoma/Leukemia Sickle Cell Disease Genetic Disease 12 Potential Approved Partner Programs Launch
Slide 19: Roadmap to Becoming a Premier Cell Engineering Solutions Provider
MaxCyte’s Roadmap to Becoming a Premier Cell Engineering Solutions Providers 19 Electroporation technology provider Comprehensive cell engineering solutions Gene Editing Tools Over $1.25b market • Key markets addressed: in vivo and ex vivo cell therapy • Other key markets addressed: Agbio, bioproces
Slide 20: Editing Assessment Services
Editing Assessment Services MaxCyte provides ex-vivo and in-vivo developers with best-in-class on-target and off-target risk assessment services Use Cases: candidate guide screening, guide RNA selection Use Cases: Off-target risk assessment, guide RNA selection, IND filings ✓ Highly sensitive ✓ Univ
Slide 21: Financial Summary
$11.7 $8.3 $7.1 $16.0 $10.3 $14.0 $10.9 $10.3 $10.3 $1.0 $0.9 $1.1 $4.6 $11.5 $6.1 2022 2023 2024 Instrument PAs Licenses Other SPL Program-related Core Revenue: (25%) Decline Core Revenue: +9% Growth Financial Summary 1. Excluding SPL Program-related revenue and reserves for excess and obsolete inv
Slide 22: Financial Summary
Financial Summary In millions, except percentages 2023 2024 Total Core Revenue $29.8 $32.5 y/y growth (25%) 9% SPL-Program Related Revenue $11.5 $6.1 y/y growth 148% (47%) Total Revenue $41.3 $38.6 y/y growth (7%) (6%) Gross Profit $36.5 $31.5 Gross Margin % 89% 82% Non-GAAP Adjusted Gross Margin %1
Slide 23: Thank you! Any questions?
Thank you! Any questions? ir@maxcyte.com 23 © 2024 MaxCyte, Inc. All Rights Reserved
Slide 24: Appendix – Historical Core Business Disclosure
Appendix – Historical Core Business Disclosure 1Q'21 2Q'21 3Q'21 4Q'21 1Q'22 2Q'22 3Q'22 4Q'22 1Q'23 2Q'23 3Q'23 4Q'23 1Q'24 2Q’24 3Q’24 4Q’24 (in $ thousands) Instrument 1,627 1,417 2,517 2,917 2,728 2,697 2,575 3,705 2,189 2,126 1,672 2,330 1,928 1,762 1,764 1,629 PAs 2,449 2,624 2,927 4,309 3,840
Slide 25: Appendix – Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted Gross Margin
Appendix – Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted gross margin 1. Adjustments include the exclusion of SPL program related revenue from Revenue, and the exclusion of reserves for excess and obsolete inventory from Cost of Goods Sold. Unaudited Reconciliation of Gross Margin to
Slide 26: Appendix – Unaudited Reconciliation of Net Loss to EBITDA
Appendix – Unaudited Reconciliation of Net Loss to EBITDA Three Months Ended Year Ended December 31, December 31, 2024 2023 2024 2023 (in thousands) Net loss $ (10,597) $ (5,277) $ (41,055) $ (37,923) Depreciation and amortization expense 1,057 1,102 4,315 4,171 Interest income (2,304) (2,818) (10,1